# Grit Bio

Source: https://onco.cc/companies/grit-bio/  
OnCo record `grit-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Grit Bio is a China-based cell therapy company that leads 3 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte therapies GT101 and GT201 and the CAR-T GT719 in cervical cancer, non-Hodgkin lymphoma and advanced solid tumours.

## Summary

Grit Bio is a late-stage biopharmaceutical company developing next-generation T-cell therapies for cancer and autoimmune disease, with headquarters in Beijing, a research centre in Shanghai and a GMP manufacturing base in Suzhou. Its pipeline includes GT101, an autologous tumour-infiltrating lymphocyte (TIL) therapy in pivotal development, GT201, a TIL therapy expressing membrane-bound IL-15, CAR-T and CAR-iNKT candidates and neoantigen cancer vaccines. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06241781 (phase 2, Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent...), NCT06948981 (phase 1/2, GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Ma...) and NCT06144671 (phase 1/2, Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Grit Biotechnology; GRIT Biotherapeutics; 沙砾生物
- Tags: ctgov-sponsor
- HQ: Beijing
- Type: cell-therapy
- Website: https://grit-bio.com/

## Sources

- Official website: https://grit-bio.com/
- ClinicalTrials.gov: trials led by Grit Bio: https://clinicaltrials.gov/search?lead=Grit%20Biotechnology

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- trials: [Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer](https://onco.cc/trials/nct06241781/), [GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies](https://onco.cc/trials/nct06948981/), [Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors](https://onco.cc/trials/nct06144671/)

---
JSON: https://onco.cc/api/v1/entities/grit-bio.json